DK575688A - Farmaceutisk praeparat med kontrolleret absorption af diltiazem og fremgangsmaade til fremstilling deraf - Google Patents

Farmaceutisk praeparat med kontrolleret absorption af diltiazem og fremgangsmaade til fremstilling deraf

Info

Publication number
DK575688A
DK575688A DK575688A DK575688A DK575688A DK 575688 A DK575688 A DK 575688A DK 575688 A DK575688 A DK 575688A DK 575688 A DK575688 A DK 575688A DK 575688 A DK575688 A DK 575688A
Authority
DK
Denmark
Prior art keywords
diltiazem
released
hours
measurement
pharmaceutically acceptable
Prior art date
Application number
DK575688A
Other languages
English (en)
Other versions
DK175591B1 (da
DK575688D0 (da
Inventor
Edward James Geoghegan
Seamus Mulligan
Donald Eugene Panoz
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE872790A external-priority patent/IE872790L/xx
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of DK575688D0 publication Critical patent/DK575688D0/da
Publication of DK575688A publication Critical patent/DK575688A/da
Application granted granted Critical
Publication of DK175591B1 publication Critical patent/DK175591B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK198805756A 1987-10-16 1988-10-14 Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf DK175591B1 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IE279187 1987-10-16
IE279187 1987-10-16
IE279087 1987-10-16
IE872790A IE872790L (en) 1987-10-16 1987-10-16 Diltiazem formulation
IE315887 1987-11-20
IE315887 1987-11-20
IE82288 1988-03-18
IE82288 1988-03-18

Publications (3)

Publication Number Publication Date
DK575688D0 DK575688D0 (da) 1988-10-14
DK575688A true DK575688A (da) 1989-04-17
DK175591B1 DK175591B1 (da) 2004-12-13

Family

ID=27452034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805756A DK175591B1 (da) 1987-10-16 1988-10-14 Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf

Country Status (10)

Country Link
EP (2) EP0320097B1 (da)
JP (1) JPH07116044B2 (da)
KR (1) KR970001656B1 (da)
AT (1) ATE241987T1 (da)
AU (2) AU615221B2 (da)
DE (1) DE3856555T2 (da)
DK (1) DK175591B1 (da)
ES (1) ES2194832T3 (da)
NZ (1) NZ226575A (da)
PT (1) PT88776B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
ES2073301T3 (es) * 1991-05-20 1995-08-01 Marion Laboratories Inc Composicion multi-capa de liberacion controlada.
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
NZ270078A (en) * 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
CA2398555C (en) * 2000-01-27 2008-04-22 Tanabe Seiyaku Co., Ltd. Sustained release preparation and method for producing the same
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition

Also Published As

Publication number Publication date
AU634660B2 (en) 1993-02-25
EP0320097B1 (en) 2003-06-04
JPH01132521A (ja) 1989-05-25
NZ226575A (en) 1991-01-29
DK175591B1 (da) 2004-12-13
AU2377588A (en) 1989-06-08
EP0320097A1 (en) 1989-06-14
DE3856555T2 (de) 2004-04-29
AU615221B2 (en) 1991-09-26
ATE241987T1 (de) 2003-06-15
PT88776B (pt) 1992-12-31
KR970001656B1 (ko) 1997-02-13
EP0856313A1 (en) 1998-08-05
AU7943591A (en) 1991-09-12
DE3856555D1 (de) 2003-07-10
JPH07116044B2 (ja) 1995-12-13
DK575688D0 (da) 1988-10-14
KR890006240A (ko) 1989-06-12
ES2194832T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
DK575688D0 (da) Farmaceutisk praeparat med kontrolleret absorption af diltiazem og fremgangsmaade til fremstilling deraf
PH22003A (en) Pharmaceutical formulation
DK352387A (da) Farmaceutisk praeparat til oral anvendelse med forsinket virkning og fremgangsmaade til fremstilling deraf
ATE43497T1 (de) Pharmazeutische formulierung mit gesteuerter absorption.
ES2058111T3 (es) Composicion de liberacion controlada de dihidrocodeina.
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
EP0250267A3 (en) Controlled absorption pharmaceutical composition
DK630287A (da) Farmaceutisk praeparat med reguleret afgivelse
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
DE3367324D1 (en) Pharmaceutical products in sustained-release form, and their preparation process
ATE172112T1 (de) Verfahren zur herstellung eines retardpräparates, das diltiazem in einer einzigen tagesdosis enthält
ATE72974T1 (de) Diltiazem-mikrokugeln, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen mit gesteuerter abgabe.
Katoh et al. T. Nabeshima1, 2, M. Hiramatsu2, T. Koide2, S. Ishihara2, A.

Legal Events

Date Code Title Description
PUP Patent expired